|
| Press Releases |
|
 |
|
| Monday, June 3, 2024 |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
|
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国 TIME誌が選出する「TIME100 Most Influential Companies of 2024」に選定されたことをお知らせします。 more info >> |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Annual fashion spotlight CENTRESTAGE draws more than 8,500 buyers
Sept 7, 2024 20:19 HKT/SGT
|
|
|
TANAKA Precious Metals Announces Executive Appointments
Sept 7, 2024 3:00 JST
|
|
|
Amazfit Launches T-Rex 3, the Ultimate Adventure Companion
Sept 6, 2024 20:00 HKT/SGT
|
|
|
周大福人寿2024年上半年 首年年化保费收入按年上升33% 持续强劲增长势头
Sept 6, 2024 17:01 HKT/SGT
|
|
|
周大福人壽2024年上半年 首年年化保費收入按年上升33% 持續強勁增長勢頭
Sept 6, 2024 16:42 HKT/SGT
|
|
|
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sept 6, 2024 16:34 JST
|
|
|
GTJAI Receives Multiple Awards in Bond Connect 2024 Awards
Sept 6, 2024 15:32 HKT/SGT
|
|
|
國泰君安國際榮獲2024年度「債券通」多項殊榮 彰顯互聯互通業務實力
Sept 6, 2024 15:25 HKT/SGT
|
|
|
国泰君安国际荣获2024年度“债券通”多项殊荣 彰显互联互通业务实力
Sept 6, 2024 15:16 HKT/SGT
|
|
|
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sept 6, 2024 15:10 JST
|
|
|
Reopening of CENTRESTAGE, Hong Kong Watch & Clock Fair and Salon de TIME
Sept 6, 2024 11:10 HKT/SGT
|
|
|
transport logistic and air cargo Southeast Asia: Fueling Regional Economic Growth
Sept 6, 2024 10:09 HKT/SGT
|
|
|
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sept 6, 2024 9:26 JST
|
|
|
How Much Do Vegan Diets Improve the Health of Dogs?
Sept 6, 2024 07:00 HKT/SGT
|
|
|
Taiwan Excellence Unveils Pioneering Medtech Innovation at Medical Fair Asia 2024
Sept 5, 2024 23:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
